A detailed history of Ferguson Wellman Capital Management, Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ferguson Wellman Capital Management, Inc holds 55,621 shares of BMY stock, worth $3.27 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
55,621
Previous 54,643 1.79%
Holding current value
$3.27 Million
Previous $2.83 Million 1.8%
% of portfolio
0.06%
Previous 0.06%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$39.66 - $51.75 $38,787 - $50,611
978 Added 1.79%
55,621 $2.88 Million
Q3 2024

Oct 18, 2024

SELL
$39.66 - $51.75 $104,742 - $136,671
-2,641 Reduced 4.61%
54,643 $2.83 Million
Q2 2024

Jul 16, 2024

SELL
$40.25 - $52.99 $94,426 - $124,314
-2,346 Reduced 3.93%
57,284 $2.38 Million
Q1 2024

Apr 09, 2024

SELL
$47.98 - $54.4 $165,626 - $187,788
-3,452 Reduced 5.47%
59,630 $3.23 Million
Q4 2023

Jan 11, 2024

SELL
$48.48 - $57.85 $214,039 - $255,407
-4,415 Reduced 6.54%
63,082 $3.24 Million
Q3 2023

Oct 12, 2023

SELL
$57.89 - $64.73 $18,756 - $20,972
-324 Reduced 0.48%
67,497 $3.92 Million
Q2 2023

Jul 11, 2023

SELL
$63.71 - $70.74 $55,682 - $61,826
-874 Reduced 1.27%
67,821 $4.34 Million
Q1 2023

Apr 20, 2023

SELL
$65.71 - $74.53 $703,556 - $797,992
-10,707 Reduced 13.48%
68,695 $4.76 Million
Q4 2022

Jan 13, 2023

BUY
$68.48 - $81.09 $2.16 Million - $2.56 Million
31,571 Added 66.01%
79,402 $5.71 Million
Q3 2022

Oct 17, 2022

SELL
$0.13 - $76.84 $83 - $49,254
-641 Reduced 1.32%
47,831 $3.4 Million
Q2 2022

Jul 14, 2022

SELL
$72.62 - $79.98 $11,038 - $12,156
-152 Reduced 0.31%
48,472 $3.73 Million
Q1 2022

Apr 14, 2022

SELL
$61.48 - $73.72 $69,165 - $82,935
-1,125 Reduced 2.26%
48,624 $3.55 Million
Q4 2021

Jan 10, 2022

SELL
$53.63 - $62.52 $1.28 Million - $1.49 Million
-23,911 Reduced 32.46%
49,749 $3.1 Million
Q3 2021

Oct 22, 2021

SELL
$59.17 - $69.31 $10,946 - $12,822
-185 Reduced 0.25%
73,660 $4.36 Million
Q2 2021

Jul 12, 2021

SELL
$61.91 - $67.42 $36,836 - $40,114
-595 Reduced 0.8%
73,845 $4.93 Million
Q1 2021

Apr 26, 2021

SELL
$59.34 - $66.74 $2.24 Million - $2.52 Million
-37,773 Reduced 33.66%
74,440 $4.7 Million
Q4 2020

Feb 04, 2021

SELL
$57.74 - $65.43 $331,947 - $376,157
-5,749 Reduced 4.87%
112,213 $6.96 Million
Q3 2020

Oct 13, 2020

BUY
$57.43 - $63.64 $617,544 - $684,320
10,753 Added 10.03%
117,962 $7.11 Million
Q2 2020

Aug 04, 2020

SELL
$54.82 - $64.09 $100,923 - $117,989
-1,841 Reduced 1.69%
107,209 $6.3 Million
Q1 2020

Apr 21, 2020

SELL
$46.4 - $67.43 $103,240 - $150,031
-2,225 Reduced 2.0%
109,050 $6.08 Million
Q4 2019

Jan 24, 2020

BUY
$49.21 - $64.19 $492,690 - $642,670
10,012 Added 9.89%
111,275 $7.14 Million
Q3 2019

Oct 15, 2019

BUY
$42.77 - $50.71 $277,577 - $329,107
6,490 Added 6.85%
101,263 $5.14 Million
Q2 2019

Jul 16, 2019

SELL
$44.62 - $49.34 $280,749 - $310,447
-6,292 Reduced 6.23%
94,773 $4.3 Million
Q1 2019

Apr 11, 2019

SELL
$45.12 - $53.8 $71,785 - $85,595
-1,591 Reduced 1.55%
101,065 $4.82 Million
Q4 2018

Jan 16, 2019

SELL
$48.76 - $63.23 $485,064 - $629,012
-9,948 Reduced 8.83%
102,656 $5.34 Million
Q3 2018

Oct 25, 2018

SELL
$55.19 - $62.25 $39,736 - $44,820
-720 Reduced 0.64%
112,604 $6.99 Million
Q2 2018

Aug 10, 2018

SELL
$50.53 - $62.98 $120,463 - $150,144
-2,384 Reduced 2.06%
113,324 $6.27 Million
Q1 2018

Apr 09, 2018

SELL
$59.92 - $68.98 $59,200 - $68,152
-988 Reduced 0.85%
115,708 $7.32 Million
Q4 2017

Jan 24, 2018

SELL
$59.94 - $65.35 $293,526 - $320,018
-4,897 Reduced 4.03%
116,696 $7.15 Million
Q3 2017

Oct 11, 2017

BUY
$55.23 - $63.74 $6.72 Million - $7.75 Million
121,593
121,593 $7.75 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Ferguson Wellman Capital Management, Inc Portfolio

Follow Ferguson Wellman Capital Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ferguson Wellman Capital Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ferguson Wellman Capital Management, Inc with notifications on news.